Replies to post #12037 on Biotech Values

[DewDiligence]

Re: U.S. ATryn timeline

You don’t have to look at the European trial because the company has given explicit guidance for the U.S. ATryn timeline:

http://library.corporate-ir.net/library/11/114/114239/items/153342/GTCB_2005_Annual_Meeting.pdf
[Slide 16]

Last patient enrolled: mid 2006.
BLA submitted: end 2006.
Approved for U.S. marketing: end 2007.

[DewDiligence]

>>Also the CD137 cancer drug being developed for the MAYO clinic. Would gtcb manufactoring this drug be similiar to gtcb manufactoring avastin or erbitux?<<

GTC could manufacture mAb’s such as Avastin and Erbitux, but I think it’s unlikely they will. GTC is focusing on plasma proteins and difficult-to-express proteins, where their production method offers the greatest benefit in safety, yield, or even feasibility relative to conventional production methods.